Pharmacomultiomics suggests new off-targets for targeted anti-cancer agents

Journal of Pharmaceutical Analysis 2026 Open access

Read full text
Authors: Xuan Linh Mai, Chae-Young Lee, Eunbyul Cho, Sunghyouk Park, Hyuk Nam Kwon
DOI: 10.1016/j.jpha.2026.101580
Cited by: 0
References: 5

Abstract

• Multi-omics of 900+ cell lines links drug sensitivity to 6 omics layers • EGFR-TKIs show novel epigenetic and metabolic off-target effects • Butyrylcarnitine serves as a potential biomarker for ibrutinib sensitivity • KPT-9274 disrupts CoA metabolism in addition to NAMPT/PAK4 inhibition • NAMPT upregulation contributes to KPT-9274 resistance

Fields of Study & Subjects

Computational Drug Discovery Methods Lung Cancer Treatments and Mutations Cancer Genomics and Diagnostics

Publication details

Journal / source
Journal of Pharmaceutical Analysis
Volume
16
Issue
6
Pages
101580–101580
Publication date
9 February 2026
Language
EN